CA
NZ
UK
AU
IND
US
The move builds on a connected ecosystem IDEXX has spent years assembling: in-clinic analyzers that use AI to read samples, cloud-based practice management software used by more than 10,000 clinics and reference laboratory services. By adding a tool that listens to appointments and drafts …
The systematic review and meta-analysis, which Intuitive announced on Sept. 8, was published in the peer-reviewedJournalAnnals of Surgery Open. It pooled data spanning 14 years and 32 countries, drawing on 13 randomized controlled trials, 21 prospective cohort studies, 101 database studies and 231 retrospective …
InnovAge (NASDAQ:INNV) shares are down 8.96% in pre-market trading to $9.70, sliding after existing shareholders affiliated withPrivate Equityfirms Apax Partners and Welsh, Carson, Anderson & Stowe priced a 10-million-share secondary offering at $9.25 per share, a discount to Tuesday's $10.60 close. The offering includes …
Solid Biosciences (NASDAQ:SLDB) shares are indicated higher again in pre-market trading, extending a rally that has been building steadily over the past several weeks.
TriSalus Life Sciences (NASDAQ:TLSI) shares are indicated sharply higher in pre-market trading after the company announced it has received FDA clearance for TriNav Advance, the newest addition to its drug delivery device lineup.
Filana Therapeutics (NASDAQ:FLNA) shares are indicated lower in pre-market trading today, giving back a portion of Monday's sharp 39.19% gain rather than reacting to any new negative development.
AstraZeneca (NYSE:AZN) shares are indicated modestly lower in pre-market trading, pulling back from Tuesday's close as investors weigh a busy newsflow day against broader strength across the healthcare sector.
Biomea Fusion (NASDAQ:BMEA) shares are indicated sharply lower in pre-market trading after the company announced it has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants in place of common stock.
Cypherpunk Technologies (NASDAQ:CYPH) shares are indicated higher in pre-market trading after the company announced the appointment of Amanda Fabiano, a veteran digital asset mining executive, to its Board of Directors.
Moderna, Inc. (NASDAQ:MRNA) shares are up 511.58 percent year to date. The move followed a series of clinical and regulatory developments during 2026, most notably positive Phase 3 results for the company's individualized cancer therapy and the first US approval of an mRNA-based influenza …
Please wait processing your request...